Armistice Capital Among Institutional Investors Targeting Small- and Mid-Cap Biopharma
Armistice Capital, which manages more than $7 billion in assets, has established a disclosed portfolio oriented toward small- and mid-cap biopharmaceutical companies, particularly those developing treatments for rare diseases, neurological disorders, and cardiovascular conditions. The fund’s 13F filings show positions in companies that occupy a market capitalization range typically characterized by higher clinical and regulatory risk than large-cap pharmaceutical companies, […]